luts

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.

Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD).

Fexapotide (NX-1207 free acid) selectively induces apoptosis to effectively reduce prostate volume at the cellular level and is applicable in the research of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [1][2][3].

Silodosin-d4 is the deuterated form of Silodosin. Silodosin (KAD 3213; KMD 3213) is a potent, selective, orally active α1A-adrenergic receptor (α1A-AR) antagonist. It exhibits high affinity for α1A-AR with a Ki of 0.036 nM, which is 162 and 50 times stronger compared to its affinities for α1B-AR and α1D-AR, with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent used in the research of LUTS/BPH.

Fexapotide (NX-1207) TFA selectively induces apoptosis, leading to a reduction in prostate volume at the cellular level. Fexapotide is applicable for research into lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).